Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

Jessica L. Mega, Tabassome Simon, Jean‐Philippe Collet, Jeffrey L. Anderson, Elliott M. Antman, Kevin P. Bliden, Christopher P. Cannon, Nicolas Danchin, Betti Giusti, Paul A. Gurbel, Benjamin D. Horne, Jean‐Sébastien Hulot, Adnan Kastrati, Gilles Montalescot, Franz‐Josef Neumann, Lei Shen, Dirk Sibbing, Philippe Gabríel Steg, Dietmar Trenk, Stephen D. Wiviott, Marc S. Sabatine

JAMA, 2010

Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, Assistance Publique – Hôpitaux de Paris, Institut National de Recherche en Santé Publique, Harvard University Press, Sinai Hospital, Hôpital Européen, University of Florence, Sorbonne Université, Laboratoire Médiations, Deutsches Herzzentrum der Charité, Deutsches Herzzentrum München, University of Freiburg, Eli Lilly (United States)

Publisher Website

Abstract

This research paper explore the methodology and findings associated with JAMA. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1117

Citations

View on Google Scholar

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

Abstract

Journal Details

Join JournalsHub

Welcome Back